Transcatheter Therapy for Mitral Regurgitation Clinical Challenges and Potential Solutions

DOI Web Site 1 Citations
  • Paul Sorajja
    From Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis (P.S., R.S.F.); Columbia University, New York (M.B.L.); Mount Sinai Medical Center, New York (D.H.A.); and St Paul’s Hospital, Vancouver, British Columbia, Canada (J.G.W.).
  • Martin B. Leon
    From Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis (P.S., R.S.F.); Columbia University, New York (M.B.L.); Mount Sinai Medical Center, New York (D.H.A.); and St Paul’s Hospital, Vancouver, British Columbia, Canada (J.G.W.).
  • David H. Adams
    From Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis (P.S., R.S.F.); Columbia University, New York (M.B.L.); Mount Sinai Medical Center, New York (D.H.A.); and St Paul’s Hospital, Vancouver, British Columbia, Canada (J.G.W.).
  • John G. Webb
    From Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis (P.S., R.S.F.); Columbia University, New York (M.B.L.); Mount Sinai Medical Center, New York (D.H.A.); and St Paul’s Hospital, Vancouver, British Columbia, Canada (J.G.W.).
  • R. Saeid Farivar
    From Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis (P.S., R.S.F.); Columbia University, New York (M.B.L.); Mount Sinai Medical Center, New York (D.H.A.); and St Paul’s Hospital, Vancouver, British Columbia, Canada (J.G.W.).

Abstract

<jats:p>Severe mitral regurgitation is a common and complex disease that is associated with an adverse prognosis. For decades, surgical treatment has been the standard of care. Recently, multiple technologies for transcatheter mitral therapy have emerged, with the potential for both repair and replacement in patients with native mitral regurgitation. Transcatheter mitral technologies have potential as solutions for unmet clinical needs. Further rigorous clinical studies are needed to determine their efficacy and safety, as well as the appropriate patient candidates. These evaluations will help to define the role of transcatheter mitral therapy as a potentially exciting new strategy to improve the lives of patients with mitral regurgitation.</jats:p>

Journal

  • Circulation

    Circulation 136 (4), 404-417, 2017-07-25

    Ovid Technologies (Wolters Kluwer Health)

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top